Case report: Patiromer-induced hypercalcemia

Patiromer is a novel potassium-binding compound which has recently received FDA approval. This ion exchange resin releases calcium when it binds potassium. We describe the development of hypercalcemia after initiation of patiromer. The calcium levels fell when the drug was stopped but recurred when...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiederkehr, Michael R., Mehta, Ankit N., Emmett, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691394/
https://www.ncbi.nlm.nih.gov/pubmed/31410346
http://dx.doi.org/10.5414/CNCS109782
_version_ 1783443371760549888
author Wiederkehr, Michael R.
Mehta, Ankit N.
Emmett, Michael
author_facet Wiederkehr, Michael R.
Mehta, Ankit N.
Emmett, Michael
author_sort Wiederkehr, Michael R.
collection PubMed
description Patiromer is a novel potassium-binding compound which has recently received FDA approval. This ion exchange resin releases calcium when it binds potassium. We describe the development of hypercalcemia after initiation of patiromer. The calcium levels fell when the drug was stopped but recurred when it was later resumed. Patiromer was again discontinued, and the serum calcium level fell back into the normal range. We believe this patient manifested patiromer-induced hypercalcemia.
format Online
Article
Text
id pubmed-6691394
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-66913942019-08-13 Case report: Patiromer-induced hypercalcemia Wiederkehr, Michael R. Mehta, Ankit N. Emmett, Michael Clin Nephrol Case Stud Case Report Patiromer is a novel potassium-binding compound which has recently received FDA approval. This ion exchange resin releases calcium when it binds potassium. We describe the development of hypercalcemia after initiation of patiromer. The calcium levels fell when the drug was stopped but recurred when it was later resumed. Patiromer was again discontinued, and the serum calcium level fell back into the normal range. We believe this patient manifested patiromer-induced hypercalcemia. Dustri-Verlag Dr. Karl Feistle 2019-08-09 /pmc/articles/PMC6691394/ /pubmed/31410346 http://dx.doi.org/10.5414/CNCS109782 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Wiederkehr, Michael R.
Mehta, Ankit N.
Emmett, Michael
Case report: Patiromer-induced hypercalcemia
title Case report: Patiromer-induced hypercalcemia
title_full Case report: Patiromer-induced hypercalcemia
title_fullStr Case report: Patiromer-induced hypercalcemia
title_full_unstemmed Case report: Patiromer-induced hypercalcemia
title_short Case report: Patiromer-induced hypercalcemia
title_sort case report: patiromer-induced hypercalcemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691394/
https://www.ncbi.nlm.nih.gov/pubmed/31410346
http://dx.doi.org/10.5414/CNCS109782
work_keys_str_mv AT wiederkehrmichaelr casereportpatiromerinducedhypercalcemia
AT mehtaankitn casereportpatiromerinducedhypercalcemia
AT emmettmichael casereportpatiromerinducedhypercalcemia

Ejemplares similares